drugset / Trial / NCT00895180
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2
Completed
80 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eli Lilly and Company · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 works in treating patients with recurrent glioblastoma multiforme.
Timeline
- Start
- 2010-07
- Primary completion
- 2012-06-22
- Completion
- 2014-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaratumab | Monoclonal antibody | — | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | — | Intravenous |